(Q51371120)

English

Alogliptin as a third oral antidiabetic drug in patients with type 2 diabetes and inadequate glycaemic control on metformin and pioglitazone: a 52-week, randomized, double-blind, active-controlled, parallel-group study.

scientific article published in December 2011

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

4 April 2018

http://europepmc.org/abstract/MED/21733058

Alogliptin as a third oral antidiabetic drug in patients with type 2 diabetes and inadequate glycaemic control on metformin and pioglitazone: a 52-week, randomized, double-blind, active-controlled, parallel-group study. (English)

1 reference

Europe PubMed Central

PubMed publication ID

4 April 2018

http://europepmc.org/abstract/MED/21733058

type 2 diabetes

0 references

0 references

1 reference

ChEBI release 2020-05-28

1 reference

based on heuristic

inferred from title

author name string

E Bosi

1

1 reference

Europe PubMed Central

PubMed publication ID

4 April 2018

http://europepmc.org/abstract/MED/21733058

G C Ellis

2

1 reference

Europe PubMed Central

PubMed publication ID

4 April 2018

http://europepmc.org/abstract/MED/21733058

C A Wilson

3

1 reference

Europe PubMed Central

PubMed publication ID

4 April 2018

http://europepmc.org/abstract/MED/21733058

P R Fleck

4

1 reference

Europe PubMed Central

PubMed publication ID

4 April 2018

http://europepmc.org/abstract/MED/21733058

publication date

1 December 2011

1 reference

Europe PubMed Central

PubMed publication ID

4 April 2018

http://europepmc.org/abstract/MED/21733058

Diabetes, Obesity and Metabolism

1 reference

Europe PubMed Central

PubMed publication ID

4 April 2018

http://europepmc.org/abstract/MED/21733058

13

1 reference

Europe PubMed Central

PubMed publication ID

4 April 2018

http://europepmc.org/abstract/MED/21733058

12

1 reference

Europe PubMed Central

PubMed publication ID

4 April 2018

http://europepmc.org/abstract/MED/21733058

1088-1096

1 reference

Europe PubMed Central

PubMed publication ID

4 April 2018

http://europepmc.org/abstract/MED/21733058

Banting Lecture. From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2011.01463.X

21 January 2018

Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2011.01463.X

21 January 2018

Is glycemic control improving in U.S. adults?

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2011.01463.X

21 January 2018

Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2011.01463.X

21 January 2018

Metformin revisited: re-evaluation of its properties and role in the pharmacopoeia of modern antidiabetic agents

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2011.01463.X

21 January 2018

Metabolic and additional vascular effects of thiazolidinediones.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2011.01463.X

21 January 2018

beta-cell failure in diabetes and preservation by clinical treatment

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2011.01463.X

21 January 2018

Metformin and pioglitazone: Effectively treating insulin resistance

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2011.01463.X

21 January 2018

Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2011.01463.X

21 January 2018

Statement by an American Association of Clinical Endocrinologists/American College of Endocrinology consensus panel on type 2 diabetes mellitus: an algorithm for glycemic control

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2011.01463.X

21 January 2018

Incretin-based therapies for type 2 diabetes mellitus

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2011.01463.X

21 January 2018

Efficacy and safety of the dipeptidyl peptidase-4 inhibitor alogliptin in patients with type 2 diabetes and inadequate glycemic control: a randomized, double-blind, placebo-controlled study

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2011.01463.X

21 January 2018

Efficacy and safety of adding the dipeptidyl peptidase-4 inhibitor alogliptin to metformin therapy in patients with type 2 diabetes inadequately controlled with metformin monotherapy: a multicentre, randomised, double-blind, placebo-controlled study

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2011.01463.X

21 January 2018

Efficacy and safety of the dipeptidyl peptidase-4 inhibitor alogliptin added to pioglitazone in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled study.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2011.01463.X

21 January 2018

Initial Combination Therapy With Alogliptin and Pioglitazone in Drug-Naïve Patients With Type 2 Diabetes

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2011.01463.X

21 January 2018

Efficacy and safety of the dipeptidyl peptidase-4 inhibitor alogliptin in patients with type 2 diabetes inadequately controlled by glyburide monotherapy

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2011.01463.X

21 January 2018

Alogliptin added to insulin therapy in patients with type 2 diabetes reduces HbA(1C) without causing weight gain or increased hypoglycaemia

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2011.01463.X

21 January 2018

Novel combination treatment of type 2 diabetes DPP-4 inhibition + metformin

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2011.01463.X

21 January 2018

Effects of vildagliptin on glucose control over 24 weeks in patients with type 2 diabetes inadequately controlled with metformin.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2011.01463.X

21 January 2018

The efficacy and safety of saxagliptin when added to metformin therapy in patients with inadequately controlled type 2 diabetes with metformin alone

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2011.01463.X

21 January 2018

Combination therapy with DPP-4 inhibitors and pioglitazone in type 2 diabetes: theoretical consideration and therapeutic potential

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2011.01463.X

21 January 2018

Saxagliptin added to a thiazolidinedione improves glycemic control in patients with type 2 diabetes and inadequate control on thiazolidinedione alone

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2011.01463.X

21 January 2018

Lower baseline glycemia reduces apparent oral agent glucose-lowering efficacy: a meta-regression analysis

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2011.01463.X

21 January 2018

Identifiers

10.1111/J.1463-1326.2011.01463.X

1 reference

Europe PubMed Central

PubMed publication ID

4 April 2018

http://europepmc.org/abstract/MED/21733058

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

4 April 2018

http://europepmc.org/abstract/MED/21733058

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q51371120&oldid=2158363555"